Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 6Triple Negative Breast Neoplasms 4Lung Neoplasms 4Endometrial Neoplasms 3Breast Neoplasms 3Neoplasms 2Neoplasm Metastasis 2Carcinosarcoma 2Advanced Solid Tumours 2Uterine Cervical Neoplasms 1Thoracic Neoplasms 1Stomach Neoplasms 1Solid Tumour Refractory to Conventional Treatment 1Small Cell Lung Carcinoma 1Salivary Gland Neoplasms 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Non Small Cell Lung Cancer NSCLC 1Neoplasms by Site 1Myelodysplastic Syndromes 1Melanoma 1Lung Diseases 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1High Grade Serous Carcinoma 1Hereditary Sensory and Autonomic Neuropathies 1

Interventions

Etoposide 3Carboplatin 3atezolizumab 2Cisplatin 2tislelizumab 1obinutuzumab 1lutetium Lu 177 dotatate 1durvalumab 1ceralasertib 1Paclitaxel 1Injections 1EC regimen 1Drug Therapy 1AMG 757 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Extensive Stage Small Cell Lung Cancer × ceralasertib × 1 year × Clear all
NCT04699838 2026-01-02

Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer

Big Ten Cancer Research Consortium

Phase 2 Recruiting
30 enrolled
Thoracic

Extensive Stage Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡